Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Down 40.1% in February

Achilles Therapeutics plc (NASDAQ:ACHL) was the recipient of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 478,300 shares, a decrease of 40.1% from the February 13th total of 797,900 shares. Approximately 1.3% of the company’s stock are sold short. Based on an average daily trading volume, of 1,070,000 shares, the short-interest ratio is currently 0.4 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Two Sigma Advisers LP lifted its stake in Achilles Therapeutics by 52.7% during the 4th quarter. Two Sigma Advisers LP now owns 34,200 shares of the company’s stock valued at $39,000 after acquiring an additional 11,800 shares during the period. Two Sigma Investments LP lifted its position in Achilles Therapeutics by 190.1% during the fourth quarter. Two Sigma Investments LP now owns 61,637 shares of the company’s stock valued at $70,000 after purchasing an additional 40,388 shares during the period. BNP Paribas Financial Markets purchased a new stake in Achilles Therapeutics in the fourth quarter worth approximately $57,000. Finally, XTX Topco Ltd bought a new stake in Achilles Therapeutics in the 4th quarter worth approximately $31,000. 56.38% of the stock is owned by institutional investors.

Achilles Therapeutics Stock Up 0.7 %

Shares of ACHL opened at $1.43 on Friday. Achilles Therapeutics has a twelve month low of $0.63 and a twelve month high of $1.44. The company has a market capitalization of $58.77 million, a P/E ratio of -0.87 and a beta of 1.25. The firm has a 50 day moving average of $1.29 and a 200 day moving average of $1.09.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.